Treatment of Acute Myeloid Leukemia with 20–30% Bone Marrow Blasts

The transition of patients with ≥20% <30% bone marrow (BM) blast from the FAB category of myelodysplasia to the family of acute myeloid leukemia (AML) according to the recent WHO classification has not resolved the argument as to whether the natural history and responsiveness to therapy of these...

Descripción completa

Detalles Bibliográficos
Autores principales: Maurillo, Luca, Buccisano, Francesco, Del Principe, Maria Ilaria, Sarlo, Chiara, Di Caprio, Luigi, Ditto, Concetta, Giannotti, Federica, Nasso, Daniela, Ceresoli, Eleonora, Postorino, Massimiliano, Refrigeri, Marco, Amadori, Sergio, Venditti, Adriano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684350/
https://www.ncbi.nlm.nih.gov/pubmed/23795270
http://dx.doi.org/10.4084/MJHID.2013.032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684350/
https://www.ncbi.nlm.nih.gov/pubmed/23795270
http://dx.doi.org/10.4084/MJHID.2013.032

Ejemplares similares